US Pharma MarketingJury awards Nektar $90M in suit against Lilly
Nektar wins $90M from Lilly in a licensing fight over rezpeg — far short of the roughly $1B it sought. Lilly plans to appeal. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…
Nektar Therapeutics won $90 million in its lawsuit against Eli Lilly over a fractured licensing deal, a win for the biotech but a far smaller sum than was sought.
Jurors in the US District Court ...
Source: Endpoints News